CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,039 enrolled
Drug / intervention
THS 2.2 +1 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02396381
NCT02396381N/ACompleted

A Randomized, Controlled, 2-arm Parallel Group, Multi-center Study, to Evaluate Biological and Functional Changes in Healthy Smokers Switching to Tobacco Heating System 2.2 (THS 2.2) Compared to Continuing Smoking Conventional Cigarettes for 26 Weeks in an Ambulatory Setting

Philip Morris Products S.A.·interventional·Posted Mar 24, 2015·Updated Jan 26, 2023

In Brief

A clinical study evaluating THS 2.2 and CC for Smoking. Completed, enrolled 1,039 participants across 19 sites.

Detailed Summary

The aim of the study is to demonstrate clinical, biological and functional health changes in smokers switching to the candidate modified risk tobacco product: Tobacco Heating System 2.2 (THS 2.2) as compared to smokers continuing smoking their conventional cigarettes (CC) over a 26-week period. To characterize the study as successful, at least 5 clinical risk endpoints should move in the direction of smoking cessation and these results would be statistically significant. The main analysis will be defined a priori (using the Hailperin-Ruger approach) and will be made between THS 2.2 use and CC use as "per actual product used" and product use categories.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmoking
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 24, 2015
Enrollment StartMar 12, 2015
Primary CompletionSep 13, 2016
Study CompletionAug 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 11.3 years ago

Interventions

THS 2.2other

Ad libitum use of THS 2.2 in an ambulatory setting for 26 weeks

CCother

Ad libitum use of CC in an ambulatory setting for 26 weeks